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Background-—Current treatment guidelines strongly recommend statin therapy for secondary prevention. However, it remains
unclear whether patients’ perceptions of cardiovascular risk, beliefs on cholesterol, or the intensity of prescribed statin therapy
differs for patients with coronary artery disease (CAD) versus cerebrovascular disease (CeVD) versus both CAD and CeVD
(CAD&CeVD).
Methods and Results-—The PALM (Patient and Provider Assessment of Lipid Management) registry collected data on statin use,
intensity, and core laboratory low-density lipoprotein cholesterol levels for 3232 secondary prevention patients treated at 133 US
clinics. Among individuals with CeVD only (n=403), CAD only (n=2202), and CeVD&CAD (n=627), no significant differences were
observed in patient-perceived cardiovascular disease risk, beliefs on cholesterol lowering, or perceived effectiveness and safety of
statin therapy. However, patients with CeVD only were less likely to receive any statin therapy (76.2% versus 86.2%; adjusted odds
ratio 0.64, 95% CI 0.45–0.91), or guideline-recommended statin intensity (34.6% versus 50.4%; adjusted odds ratio 0.60, 95% CI
0.45–0.81) than those with CAD only. Individuals with CeVD only were also less likely to achieve low-density lipoprotein cholesterol
<100 mg/dL (59.2% versus 69.7%; adjusted odds ratio 0.79, 95% CI 0.64–0.99) than individuals with CAD alone. There were no
significant differences in the use of any statin therapy or guideline-recommended statin intensity between individuals with
CAD&CeVD and those with CAD only.
Conclusions-—Despite lack of significant differences in patient-perceived cardiovascular risk or statin beliefs, patients with CeVD
were significantly less likely to receive higher intensity statin or achieve low-density lipoprotein cholesterol <100 mg/dL than
those with CAD only. ( J Am Heart Assoc. 2019;8:e013229. DOI: 10.1161/JAHA.119.013229.)
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C urrent lipid guidelines strongly recommend statintherapy for secondary prevention in patients with
atherosclerotic cardiovascular disease (ASCVD), including
coronary artery disease (CAD) and cerebrovascular disease
(CeVD).1–3 Despite the overwhelming evidence that statins
are highly beneficial in preventing recurrent ischemic events,
secondary prevention patients are often untreated or
undertreated with lower-than-recommended statin intensity
in community practice.4–10 While appropriate statin therapy is
an important goal in patients with CeVD,3 it is unclear
whether CeVD patients are treated differently from those with
CAD.
The PALM (Patient and Provider Assessment of Lipid
Management) registry is a nationwide contemporary outpatient
registry of individuals with ASCVD or at high risk for ASCVD in
the United States. Using PALM registry first we examined
differences in patient perceptions of cardiovascular risks, beliefs
on the effectiveness and safety of statin drugs, tolerability and
reported symptoms following statin use among patients with
CeVD only, both CAD and CeVD (CAD&CeVD), or CAD only.
Second, we compared overall statin use, and guideline-
recommended statin therapy and low density lipoprotein
cholesterol (LDL-C) levels, by the underlying ASCVD condition
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before and after adjusting for differences in patient character-
istics, perceptions, and beliefs.
Methods
The authors declare that all supporting data are available
within the article and its online supplementary files.
Study Design and Data Sources
Details of the design and conduct of the PALM registry have
been previously described.11 A total of 7938 patients were
enrolled from 140 cardiology, primary care, and endocrinology
practices in the United States between May 2015 and
November 2015. Patient sociodemographic characteristics,
comorbidities, and current medications including statin use
and dosage were abstracted from the medical record by study
coordinators at each site. Core laboratory lipid panels were
performed by LabCorp (Burlington, NC). PALM captured
detailed information about patients’ prior experiences with
lipid-lowering therapy. The survey also assessed patients’
income and education, perceived risk of cardiovascular
disease, beliefs about cholesterol and lipid-lowering therapy,
and self-reported intolerances to statins and prior statin
adverse effects (overall survey response rate 95.3%). Patient
numeracy was assessed using the Subjective Numeracy
Scale, a validated self-reported instrument to quantify self-
reported numeracy, to indicate how well patients can
understand concepts such as cardiovascular risk and risk
reduction.12,13 All patients provided written informed consent
before participation. The Duke Institutional Review Board
provided approval for coordinating center activities, and
individual sites obtained approval from their local institutional
review board or from the central institutional review board for
the study before enrolling patients in the PALM registry.
Study Population and Variables of Interest
The current analyses included 3232 patients with CeVD only,
CAD&CeVD, or CAD only from 133 sites in the PALM registry.
CeVD was defined as a medical history of prior stroke,
transient ischemic attack, or carotid artery stenosis with or
without revascularization. CAD was defined as a medical
history of coronary artery disease, prior myocardial infarction,
coronary artery bypass grafting, or percutaneous coronary
intervention. The primary outcomes were statin use and
dosage, use of guideline-recommended statin intensity, and
LDL-C levels <100 mg/dL.1 Statin intensity was assessed
based on whether the patient was on at least the guideline-
recommended statin dose according to the 2013 American
Heart Association/American College of Cardiology Guideline,
which was the guideline in place at the time of the survey. If
patients were recommended for high-intensity statin and were
on high-intensity statin, or recommended for moderate-
intensity statin and were on either a moderate- or high-
intensity statin, they were considered to be on guideline-
recommended statin dose. High-intensity statin use was
defined as atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily;
and moderate-intensity statin use was defined as 10 mg
≤atorvastatin <40 mg, 5 mg ≤rosuvastatin <20 mg, simvas-
tatin ≥20 mg, pravastatin ≥40 mg, lovastatin ≥40 mg, fluvas-
tatin ≥80 mg, or pitavastatin ≥2 mg daily.
Statistical Analysis
Medians (25th–75th percentile [p25–p75]) and frequencies
(percentages) were used to describe the distribution of
continuous and categorical variables, respectively. Baseline
characteristics, patient perceptions of cardiovascular risk,
beliefs about statins, and patient-reported statin-associated
symptoms were compared across 3 groups (CeVD only,
CAD&CeVD, and CAD only) using Pearson v2 test or Fisher
exact test for categorical variables and Kruskal-Wallis test for
continuous variables.
Multivariable logistic regression models were performed
to investigate the association between underlying ASCVD
(CeVD only, CAD&CeVD, or CAD only) and outcomes (statin
use, guideline-recommended statin therapy, and LDL-C
<100 mg/dL). Adjusted odds ratio (aOR) and 95% CI were
Clinical Perspective
What Is New?
• Current lipid guidelines strongly recommend statin therapy
for secondary prevention in patients with atherosclerotic
cardiovascular disease, including coronary artery disease
and cerebrovascular disease.
• While appropriate statin therapy is an important goal, it is
unclear whether patients with cerebrovascular disease are
treated differently from those with coronary artery disease.
What Are the Clinical Implications?
• Despite no significant differences in patient-perceived
cardiovascular disease risk, beliefs on cholesterol lowering,
or perceived effectiveness and safety of statin therapy,
patients with cerebrovascular disease were significantly less
likely to receive higher intensity statin or achieve low-
density lipoprotein cholesterol <100 mg/dL than those with
coronary artery disease only.
• Greater efforts are needed to enhance clinician adoption
and adherence to guidelines for patients with cerebrovas-
cular disease.
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Table 1. Characteristics of Patients
CeVD Only n=403 CAD&CeVD n=627 CAD Only n=2202 P Value
Age, median (p25 to p75), y 70 (63–76) 72 (66–78) 70 (63–77) <0.001
Range 32 to 97 39 to 94 25 to 99
Women, % 222 (55.1) 213 (34.0) 735 (33.4) <0.001
Race, %
White 331 (82.1) 552 (88.0) 1940 (88.1) <0.001
Black 58 (14.4) 63 (10.1) 213 (9.7)
Asian 12 (3.0) 11 (1.8) 46 (2.1)
Other 2 (0.5) 1 (0.2) 3 (0.1)
Ethnicity/Hispanic, % 41 (10.2) 39 (6.2) 140 (6.4) 0.02
Insurance, %
Private 212 (52.6) 349 (55.7) 1264 (57.5) 0.14
Government 187 (46.4) 274 (43.7) 902 (41.1)
Other 4 (1.0) 4 (0.6) 31 (1.4)
Education, %
Middle school 30 (7.9) 44 (7.4) 149 (7.2) 0.69
High school 112 (29.4) 184 (31.1) 588 (28.4)
Some college 100 (26.3) 174 (29.4) 573 (27.6)
College graduate 84 (22.1) 119 (20.1) 483 (23.3)
Postgraduate degree 55 (14.4) 71 (12.0) 281 (13.6)
Income, %
<$35 000 101 (27.6) 144 (24.6) 480 (23.5) 0.004
$35 000 to $74 999 78 (21.3) 128 (21.8) 419 (20.5)
$75 000 to $99 999 17 (4.6) 41 (7.0) 157 (7.7)
$100 000 33 (9.0) 54 (9.2) 292 (14.3)
Do not know or refused 137 (37.4) 219 (37.4) 695 (34.0)
Numeracy score, median (p25 to p75) 16 (11–20) 16 (12–21) 16 (12–21) 0.19
Body mass index ≥30 kg/m2, % 169 (42.4) 282 (45.2) 1051 (47.9) 0.09
Medical history, %
Prior myocardial infarction 0 209 (33.3) 799 (36.3) . . .
Prior coronary artery bypass graft 0 206 (32.9) 592 (26.9) . . .
Prior percutaneous coronary intervention 0 307 (49.0) 1107 (50.3) . . .
Prior stroke 158 (39.2) 183 (29.2) 0 . . .
Prior transient ischemic attack 106 (26.3) 145 (23.1) 0 . . .
Carotid stenosis 199 (49.4) 426 (67.9) 0 . . .
Peripheral artery disease 47 (11.7) 152 (24.2) 189 (8.6) <0.001
Hypertension 323 (80.2) 561 (89.5) 1869 (84.9) <0.001
Diabetes mellitus 154 (38.2) 277 (44.2) 857 (38.9) 0.05
Chronic kidney disease 59 (14.6) 107 (17.1) 251 (11.4) <0.001
Dialysis 5 (1.2) 6 (1.0) 16 (0.7) 0.54
Elevated liver function 16 (4.0) 23 (3.7) 75 (3.4) 0.83
Myopathy 15 (3.7) 43 (6.9) 131 (6.0) 0.10
Continued
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presented with CAD only as the reference group for
comparison. Generalized estimating equations with a com-
pound symmetry working correlation matrix and empirical
(sandwich) standard error estimates were used to account
for clustering of patients within sites. The statin therapy
model adjusted for clinically relevant variables possibly
associated with statin therapy or used in previous PALM
studies.4,14,15
Covariates included age, sex, race, ethnicity, insurance,
education, annual household income, numeracy score, med-
ical history of peripheral artery disease, hypertension,
diabetes mellitus, chronic kidney disease/dialysis, elevated
liver function, history of myopathy, tobacco use, patient’s
perceptions of heart attack or stroke, beliefs about high
cholesterol, beliefs about statin safety and effectiveness,
patient-reported trust in clinician in Likert scales, clinic
location, and provider type. Missing data for most of the
covariates were rare (<1%), except for the patient survey
questions (4.4%–14.5%). Multiple imputation was used and
the results from the multivariable models were combined
across 20 imputed data sets. Similar covariates were included
in the LDL-C model, except for patient’s perceptions, beliefs,
trust in clinician because these variables are not expected to
affect LDL-C levels directly except through statin treatment. In
addition to the overall population, subgroup analyses were
performed by age (≤75 and >75 years) for all outcomes and
by LDL-C levels (<100 and ≥100 mg/dL) for statin therapy, by
fitting separate models for each subgroup.
All statistical analyses were performed using SAS statis-
tical software version 9.4 (SAS Institute Inc, Cary NC). All P
values are 2-sided, with P<0.05 considered statistically
significant.
Results
Baseline characteristics of the study population are shown in
Table 1. Of 3232 secondary prevention patients evaluated
in PALM, 403 had CeVD only, 627 CAD&CeVD, and 2202
CAD only. The median ages were 70, 72, and 70 years for
the 3 cohorts, respectively (P<0.001). More than half of
patients with CeVD only were women, whereas only one
third were women in the CAD&CeVD or CAD only groups.
Patients with CeVD also had lower incomes and a higher
proportion of race/ethnicity minorities. Besides their under-
lying conditions, 11.7% of patients with CeVD had peripheral
artery disease, 80.2% hypertension, 38.2% diabetes mellitus,
and 14.6% chronic kidney disease. There were no significant
differences in insurance, education, numeracy score, medical
history of elevated liver function, or myopathy across the 3
groups.
Patient Perceptions of Cardiovascular Risk,
Beliefs on Statin Drugs, and Reported Symptoms
Despite differences in their underlying conditions, there were
no significant differences in patients’ perceptions of cardio-
vascular disease risk, beliefs about cholesterol, the effective-
ness and safety of statin therapy, and trust in physicians’
decision about their medical care, although patients with
CeVD were less likely to believe statins can cause muscle
aches or pain (Table 2). Among those who were currently or
previously taking statin therapy, patients with CeVD were less
likely to report hives/itching. In addition, nausea, vomiting,
stomach upset, or constipation were less likely to be reported
by CeVD patients among those previously taking statins.
Table 1. Continued
CeVD Only n=403 CAD&CeVD n=627 CAD Only n=2202 P Value
Tobacco use
Current 48 (11.9) 76 (12.1) 234 (10.6) 0.002
Quit within past year 3 (0.8) 7 (1.1) 45 (2.0)
Quit >1 y ago 157 (39.1) 311 (49.6) 961 (43.6)
Never 194 (48.3) 233 (37.2) 962 (43.7)
Site characteristics, %
Rural 41 (10.2) 43 (6.9) 213 (9.7) 0.08
Provider type
Cardiologist 212 (52.6) 441 (70.3) 1518 (68.9) <0.001
Primary care/family medicine 163 (40.5) 167 (26.6) 612 (27.8)
Endocrinology 16 (4.0) 6 (1.0) 27 (1.2)
Other 12 (3.0) 13 (2.1) 45 (2.0)
CAD indicates coronary artery disease; CeVD, cerebrovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
DOI: 10.1161/JAHA.119.013229 Journal of the American Heart Association 4
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Table 2. Patient Perceptions of Cardiovascular Risks, Beliefs on Statin Drugs, and Reported Symptoms
CeVD Only n=383 CAD&CeVD n=601 CAD Only n=2106 P Value
Patient perceptions, %
How often do think or worry that may have a heart attack or stroke?
Often 54 (14.1) 59 (9.8) 246 (11.7) 0.45
Occasionally 104 (27.2) 158 (26.3) 574 (27.3)
Rarely 106 (27.7) 164 (27.3) 591 (28.1)
Never 97 (25.3) 179 (29.8) 576 (27.4)
Missing 22 (5.7) 41 (6.8) 119 (5.7)
Patient beliefs, %
People with high cholesterol are more likely to have a heart attack or stroke than people with low cholesterol
Strongly agree 82 (21.4) 108 (18.0) 456 (21.7) 0.34
Agree 205 (53.5) 341 (56.7) 1118 (53.1)
Neither agree nor disagree 16 (4.2) 25 (4.2) 116 (5.5)
Disagree 14 (3.7) 24 (4.0) 81 (3.9)
Strongly disagree 20 (5.2) 18 (3.0) 72 (3.4)
Do not know/not sure 24 (6.3) 47 (7.8) 147 (7.0)
Missing 22 (5.7) 38 (6.3) 116 (5.5)
Statins are effective in reducing the risk of heart disease and stroke
Strongly agree 50 (13.1) 93 (15.5) 308 (14.6) 0.15
Agree 193 (50.4) 323 (53.7) 1149 (54.6)
Neither agree nor disagree 27 (7.1) 47 (7.8) 190 (9.0)
Disagree 9 (2.4) 8 (1.3) 35 (1.7)
Strongly disagree 7 (1.8) 9 (1.5) 32 (1.5)
Do not know/not sure 62 (16.2) 70 (11.7) 223 (10.6)
Missing 35 (9.1) 51 (8.5) 169 (8.0)
Stains are safe medications
Strongly agree 25 (6.5) 39 (6.5) 137 (6.5) 0.09
Agree 149 (38.9) 247 (41.1) 932 (44.3)
Neither agree nor disagree 67 (17.5) 96 (16.0) 357 (17.0)
Disagree 18 (4.7) 32 (5.3) 133 (6.3)
Strongly disagree 8 (2.1) 15 (2.5) 25 (1.2)
Do not know/not sure 76 (19.8) 107 (17.8) 319 (15.2)
Missing 40 (10.4) 65 (10.8) 203 (9.6)
I think statins can cause diabetes mellitus
Strongly agree 3 (0.8) 7 (1.2) 11 (0.5) 0.23
Agree 20 (5.2) 40 (6.7) 134 (6.4)
Neither agree nor disagree 47 (12.3) 59 (9.8) 276 (13.1)
Disagree 70 (18.3) 108 (18.0) 390 (18.5)
Strongly disagree 36 (9.4) 37 (6.2) 137 (6.5)
Do not know/not sure 166 (43.3) 280 (46.6) 942 (44.7)
Missing 41 (10.7) 70 (11.7) 216 (10.3)
I think statins can cause muscle aches or pain
Strongly agree 42 (11.0) 84 (14.0) 229 (10.9) 0.04
Continued
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Table 2. Continued
CeVD Only n=383 CAD&CeVD n=601 CAD Only n=2106 P Value
Agree 96 (25.1) 146 (24.3) 662 (31.4)
Neither agree nor disagree 41 (10.7) 64 (10.7) 219 (10.4)
Disagree 47 (12.3) 62 (10.3) 190 (9.0)
Strongly disagree 9 (2.4) 14 (2.3) 49 (2.3)
Do not know/not sure 108 (28.2) 166 (27.6) 556 (26.4)
Missing 40 (10.4) 65 (10.8) 201 (9.5)
I think statins can cause liver damage
Strongly agree 22 (5.7) 27 (4.5) 85 (4.0) 0.41
Agree 89 (23.2) 133 (22.1) 547 (26.0)
Neither agree nor disagree 54 (14.1) 85 (14.1) 284 (13.5)
Disagree 33 (8.6) 39 (6.5) 144 (6.8)
Strongly disagree 4 (1.0) 10 (1.7) 21 (1.0)
Do not know/not sure 138 (36.0) 242 (40.3) 812 (38.6)
Missing 43 (11.2) 65 (10.8) 213 (10.1)
I think statins can cause memory loss
Strongly agree 4 (1.0) 11 (1.8) 41 (2.0) 0.56
Agree 39 (10.2) 74 (12.3) 230 (10.9)
Neither agree nor disagree 58 (15.1) 77 (12.8) 324 (15.4)
Disagree 61 (15.9) 79 (13.1) 277 (13.2)
Strongly disagree 17 (4.4) 19 (3.2) 75 (3.6)
Do not know/not sure 160 (41.8) 277 (46.1) 947 (45.0)
Missing 44 (11.5) 64 (10.7) 212 (10.1)
How much would you say you trust your doctors’ decision about your medical care
Completely trust 241 (62.9) 396 (65.9) 1412 (67.1) 0.53
Generally trust 111 (29.0) 165 (27.5) 556 (26.4)
Neither trust nor distrust 5 (1.3) 6 (1.0) 24 (1.1)
Generally distrust 8 (2.1) 4 (0.7) 22 (1.0)
Completely distrust 15 (3.9) 23 (3.8) 69 (3.3)
Missing 3 (0.8) 7 (1.2) 23 (1.1)
Report symptoms, %
If currently taking a statin N=292 N=489 N=1774
Muscle aches, cramps 85 (29.1) 159 (32.5) 545 (30.7) 0.72
Missing 20 (6.9) 24 (4.9) 123 (6.9)
Memory loss, forgetfulness, or confusion 34 (11.6) 68 (13.9) 188 (10.6) 0.16
Missing 21 (7.2) 24 (4.9) 123 (6.9)
Weakness 43 (14.7) 68 (13.9) 197 (11.1) 0.10
Missing 21 (7.2) 24 (4.9) 125 (7.1)
Nausea, vomiting, stomach upset 18 (6.2) 22 (4.5) 74 (4.2) 0.30
Missing 21 (7.2) 24 (4.9) 125 (7.1)
Constipation 28 (9.6) 54 (11.0) 144 (8.1) 0.15
Missing 21 (7.2) 24 (4.9) 125 (7.1)
Fatigue 46 (15.8) 90 (18.4) 277 (15.6) 0.43
Continued
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Meanwhile, there were no statistically significant differences
in reported symptoms such as muscle aches, memory loss,
weakness, or fatigue across 3 cohorts. The reported symp-
toms were similar across 3 cohorts in the subgroup analyses
by guideline-recommended statin therapy and LDL-C levels
(Table S1).
Statin Use and LDL-C Levels
Overall, 84.3% of patients received statin therapy and 48.3%
were on guideline-recommended statin intensity. Fewer
patients with CeVD only were received statin therapy (76.2%
versus 82.6% versus 86.2%, P<0.001) or treated at the
guideline-recommended intensity (34.6%, versus 49.8% versus
50.4%, P<0.001) than individuals with CAD&CeVD or those
with CAD only. Only 6.8% of patients with CeVD had
previously taken a statin and then discontinued it as
compared with 9.8% of those with CAD&CeVD or 7.2% of
those with CAD only. In contrast, more patients with CeVD
had never taken a statin at all (17.0% versus 8.8% versus
8.6%, P<0.001). After risk adjustment, patients with CeVD
only were less likely to be treated with any statin (aOR 0.64,
95% CI 0.45–0.91) or at the guideline-recommended intensity
(aOR 0.60, 95% CI 0.45–0.81) compared with CAD only
patients. Similar trends of lower statin use and statin intensity
were observed in subgroup analyses by age and LDL-C levels,
although the differences were not statistically significant in
older patients and those with LDL≥100 mg/dL (Figures 1 and
2). Meanwhile, there were no statistically significant differ-
ences in any statin use and statin intensity between patients
with CAD&CeVD versus CAD only.
The median (p25–p75) LDL-C levels were 90 (73–114), 88
(69–111), and 83 (66–107) mg/dL for patients with CeVD
only, CAD&CeVD, or CAD only, respectively (P<0.001). In
addition, 59.2% of patients with CeVD only had LDL-C levels
<100 mg/dL (Figure 3). In contrast, 63.7% of patients with
CAD&CeVD and 69.7% with CAD only had LDL-C <100 mg/
dL. After risk adjustment, patients with CeVD only (aOR 0.79,
95% CI 0.64–0.99) or CAD&CeVD (aOR 0.73, 95% CI 0.61–
0.87) were less likely to have an LDL-C <100 mg/dL as
compared with CAD only patients. Similar results were seen in
the subgroup analysis by age ≤75 or >75 years, although the
difference was not statistically significant in patients aged
>75 years.
Table 2. Continued
CeVD Only n=383 CAD&CeVD n=601 CAD Only n=2106 P Value
Missing 21 (7.2) 24 (4.9) 124 (7.0)
Hives and/or itching 4 (1.4) 26 (5.3) 53 (3.0) 0.008
Missing 21 (7.2) 24 (4.9) 125 (7.1)
Other 0 4 (0.8) 19 (1.1) 0.01
Missing 21 (7.2) 24 (4.9) 125 (7.1)
If previously taking a statin N=26 N=59 N=152
Muscle aches, cramps 12 (46.2) 36 (61.0) 81 (53.3) 0.51
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Memory loss, forgetfulness, or confusion 2 (7.7) 8 (13.6) 12 (7.9) 0.47
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Weakness 2 (7.7) 16 (27.1) 41 (27.0) 0.11
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Nausea, vomiting, stomach upset 0 5 (8.5) 9 (5.9) 0.04
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Constipation 1 (3.9) 7 (11.9) 11 (7.2) 0.03
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Fatigue 2 (7.7) 16 (27.1) 40 (26.3) 0.12
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Hives and/or itching 1 (3.9) 6 (10.2) 8 (5.3) 0.04
Missing 2 (7.7) 2 (3.4) 9 (5.9)
Other 0 0 5 (3.5) 0.10
Missing 2 (7.7) 2 (3.4) 9 (5.9)
DOI: 10.1161/JAHA.119.013229 Journal of the American Heart Association 7
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Discussion
Statins are the mainstay of secondary prevention for both
CAD and CeVD patient populations.1–3 Our study of real-world
clinical practice found significant gaps in the usage and
dosing of statins in patients with different types of ASCVD.
Treatment patterns were less optimal for patients with CeVD
only versus CAD only. Nearly 25% of individuals with CeVD
only who met the guideline indication for secondary preven-
tion failed to receive any statin therapy. Even among those
taking statins, under-dosing was common. Only one third of
patients with CeVD only were on the statin intensity recom-
mended by the guidelines. Except for less concerns about
muscle symptoms or reported symptoms from statin use in
individuals with CeVD only, no significant differences were
observed in patient perceptions and beliefs about cholesterol
lowering. Collectively, these findings suggest room for improve-
ment in clinical management of lipids in patients with CeVD.
The reasons for statin underuse are complex.16–28
Although some cite statin intolerance and concerns of
adverse effects as potential causes,7 we found similar patient
beliefs in safety of statins among those with CAD and/or
CeVD. Importantly, more patients with CeVD only never took
a statin and or had discontinued statin therapy than those
with CAD only. Among those currently or previously taking a
statin, similar rates of symptoms were reported in patients
with CeVD only, CAD only, or both, including muscle pain,
cognitive decline, weakness, nausea, vomiting, or constipa-
tion. While uncommon, patients with CeVD experienced less
hives or itching. Similar results were found in the analyses by
statin intensity and LDL-C level.
Patients with CeVD only reported similarly high perceived
risk of ASCVD, and shared similar beliefs in the role of high
cholesterol on heart attack or stroke, as well as the effective-
ness and safety of statin therapy as those with CAD only. There
were no differences in perceived long-term side effects such as
developing diabetes mellitus, causing liver damage, and
cognitive decline. Additionally, >92% of patients trust their
physicians. While previous studies suggested that lower-
income individuals and minorities are less likely to receive
statins and more likely to discontinue statins, the differences in
statin use between CeVD and CAD persisted after risk
Figure 1. Any statin use by underlining atherosclerotic cardiovascular disease. Adjust for age, sex, race,
ethnicity, insurance, education, annual household income, numeracy score, medical history of peripheral
artery disease, hypertension, diabetes mellitus, chronic kidney disease/dialysis, elevated liver function,
myopathy, tobacco use status, patient’s perceptions of heart attack or stroke, beliefs about high
cholesterol, beliefs about statin safety and effectiveness, trust in clinician, clinic location (rural/urban),
provider type, and clinic-level clustering effect. CAD indicates coronary artery disease; CeVD, cerebrovas-
cular disease; LDL-C, low density lipoprotein cholesterol; OR, odds ratio.
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adjustment.5,29 Therefore, the decision for not prescribing
statin therapy is unlikely to be attributable to patient charac-
teristics and concerns alone.
Similar to the 2013 and 2018 American College of
Cardiology/American Heart Association cholesterol guideli-
nes, the stroke prevention guidelines in patients with stroke
or transient ischemic attack also recommend statin therapy
with intensive lipid-lowering effects to reduce the risk of
recurrent stroke and cardiovascular events.1–3 As of today,
the SPARCL (Stroke Prevention by Aggressive Reduction in
Cholesterol Levels) study remains the only clinical trial
examining high-intensity statin for secondary prevention in
patients with stroke or transient ischemic attack.16 Ator-
vastatin 80 mg reduced stroke by 16% and major cardio-
vascular events by 20% as compared with placebo. Yet,
high-intensity statin was associated with a small but
significant increase in the incidence of hemorrhagic stroke
(hazard ratio 1.68, 95% CI 1.09–2.59), which was
associated with a baseline history of hemorrhagic stroke
or poorly controlled hypertension, but no differences in the
incidence of fatal hemorrhagic stroke between the
groups.22 Meta-analyses of clinical trials data including
the SPARCL found a slight increase in intracerebral
hemorrhage, which was outweighed 50-fold by the number
of stroke major vascular events prevented.30 While we were
unable to determine the reasons behind treatment deci-
sions, providers’ preferences and concern over hemorrhage
risk, whether unfounded or not, may have contributed to
the statin underutilization or under-dosing in patients with
CeVD. It may also be that cardiologists are involved in the
care of many CAD patients, whereas neurologists or
surgeons may be the primary specialists caring for CeVD.
The risk aversion of hemorrhagic stroke may also explain
the treatment-risk paradox in patients with CAD&CeVD, who
were less likely to receive statin and achieve LDL-C
<100 mg/dL despite their higher risk profiles. Further
Figure 2. Guideline-recommended statin therapy by underlining atherosclerotic cardiovascular disease.
Guideline-recommended statin therapy is defined as patient who meets the recommendation for high-
intensity statin therapy is on high-intensity statin or patient who meets the recommendation for moderate-
intensity statin is on either high- or moderate-intensity statin. High intensity: atorvastatin ≥40 mg or
rosuvastatin ≥20 mg. Moderate intensity: 10≤atorvastatin<40 mg, 5≤rosuvastatin<20, simvas-
tatin≥20 mg, pravastatin ≥40 mg, lovastatin ≥40 mg, fluvastatin ≥80 mg, or pitavastatin ≥2 mg. Adjust
for age, sex, race, ethnicity, insurance, education, annual household income, numeracy score, medical
history of peripheral artery disease, hypertension, diabetes mellitus, chronic kidney disease/dialysis,
elevated liver function, myopathy, tobacco use status, patient’s perceptions of heart attack or stroke,
beliefs about high cholesterol, beliefs about statin safety and effectiveness, trust in clinician, clinic location
(rural/urban), provider type, and clinic-level clustering effect. CAD indicates coronary artery disease; CeVD,
cerebrovascular disease; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.
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research is needed to evaluate provider preferences and
beliefs and how these factors may have influenced
treatment decision making.
This study has several limitations. First, while we used an
objective measure of statin use abstracted from the medical
record, we did not have access to data on documented
reasons for not prescribing statins. Second, we were unable
to determine the type and timing of the prior stroke event.
Although there are no firm recommendations on the use of
statins in intracerebral hemorrhage, a medical history of
hemorrhagic stroke may have influenced some clinicians.
Some strokes may not have an atherosclerotic origin.
However, all stroke patients should be considered for
cholesterol lowering therapy unless contraindicated. A related
issue is the inclusion of carotid stenosis in CeVD, where the
degree of stenosis and cannot be determined in the registry.
Third, the PALM registry is targeted at outpatient practice with
primary care, cardiology, and endocrinology providers. There-
fore, the practice patterns may be different for patients seen
by neurologists, especially for those with CeVD only or
CAD&CeVD. Our results therefore cannot be extrapolated to
patients treated by neurologists or vascular neurologists. In
addition, individuals with CeVD are in general older than those
with CAD in community practice, yet the age differences are
relatively small in our cohort, possibly reflecting patient
section in the registry. Finally, the PALM is a voluntary
outpatient registry. Participating providers may have been
more likely to focus on lipid management. While these study
results might not be extrapolated to non-participating
providers, it could be argued that statin therapy could be
even worse in community clinics, thus further highlighting the
challenge in implementation of evidence-based statin therapy
in real-world practice.
Conclusion
In conclusion, patients with CeVD only were less likely to
receive statin therapy at the guideline-recommended dose, or
to achieve LDL-C <100 mg/dL than patients with CAD only
despite similar patient-perceived risk of future ASCVD events,
beliefs in the safety, and reported side effects of statins.
Future efforts are needed to promote optimal use of statin
therapy in patients with cerebrovascular disease and stroke.
Sources of Funding
This study was supported by Sanofi Pharmaceuticals and
Regeneron Pharmaceuticals.
Figure 3. LDL-C <100 mg/dL by underlining atherosclerotic cardiovascular disease. Adjust for age, sex, race,
ethnicity, insurance, education, annual household income, medical history of peripheral artery disease,
hypertension, diabetes mellitus, chronic kidney disease/dialysis, elevated liver function, myopathy, tobacco use
status, clinic location (rural/urban), provider type, and clinic-level clustering effect. CAD indicates coronary
artery disease; CeVD, cerebrovascular disease; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.
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Table S1. Reported symptoms across 3 cohorts in the subgroup analyses by guideline-
recommended statin therapy and LDL-C levels. 
 CeVD only  CAD&CeVD CAD only  P 
value 
On guideline-recommended statin 
therapy, % 
    
If currently taking a statin N=127 N=278 N=997  
    Muscle aches, cramps 34 (28.8) 86 (33.0) 267 (28.9) 0.44 
    Memory loss, forgetfulness, or 
confusion 
10 (8.6) 38 (14.6) 97 (10.5) 0.12 
    Weakness     13 (11.1) 39 (14.9) 104 (11.3) 0.26 
    Nausea, vomiting, stomach upset 6 (5.1) 13 (5.0) 36 (3.9) 0.66 
    Constipation 12 (10.3) 35 (13.4) 82 (8.9) 0.10 
    Fatigue 15 (12.8) 49 (18.8) 147 (15.9) 0.32 
    Hives and/or itching 1 (0.9) 19 (7.3) 27 (2.9) 0.001 
    Other 0 3 (1.2) 12 (1.3) 0.06 
If previously taking a statin N=2 N=7 N=26  
    Muscle aches, cramps 0 2 (33.3) 9 (39.1) 0.15 
    Memory loss, forgetfulness, or 
confusion 
0 0 2 (8.7) 0.54 
    Weakness     0 1 (16.7) 6 (26.1) 0.23 
    Nausea, vomiting, stomach upset 0 1 (16.7) 2 (8.7) 0.34 
    Constipation 1 (50.0) 0 3 (13.0) 0.11 
    Fatigue 0 1 (16.7) 5 (21.7) 0.27 
    Hives and/or itching 0 0 0 - 
    Other 0 0 0 - 
Not on any statin therapy or not on 
guideline-recommended statin 
therapy, % 
    
If currently taking a statin N=164 N=207 N=759  
    Muscle aches, cramps 51 (33.3) 71 (35.5) 271 (38.2) 0.48 
    Memory loss, forgetfulness, or 
confusion 
24 (15.7) 29 (14.5) 89 (12.6) 0.52 
    Weakness     30 (19.6) 28 (14.0) 89 (12.5) 0.07 
    Nausea, vomiting, stomach upset 12 (7.8) 9 (4.5) 38 (5.4) 0.37 
    Constipation 16 (10.5) 18 (9.0) 61 (8.6) 0.77 
    Fatigue 30 (19.6) 40 (20.0) 128 (18.1) 0.78 
    Hives and/or itching 3 (2.0) 7 (3.5) 24 (3.4) 0.64 
    Other 0 1 (0.5) 7 (1.0) 0.09 
If previously taking a statin N=24 N=52 N=126  
    Muscle aches, cramps 12 (54.6) 34 (66.7) 72 (60.0) 0.57 
    Memory loss, forgetfulness, or 
confusion 
2 (9.1) 8 (15.7) 10 (8.3) 0.35 
    Weakness     2 (9.1) 15 (29.4) 35 (29.2) 0.14 
    Nausea, vomiting, stomach upset 0 4 (7.8) 7 (5.8) 0.06 
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    Fatigue 2 (9.1) 15 (29.4) 35 (29.2) 0.14 
    Hives and/or itching 1 (4.6) 6 (11.8) 8 (6.7) 0.04 
    Other 0 0 5 (4.2) 0.09 
LDL-C <100mg/dL, %     
If currently taking a statin N=195 N=339 N=1300  
    Muscle aches, cramps 54 (29.7) 109 (34.0) 355 (29.7) 0.33 
    Memory loss, forgetfulness, or 
confusion 
22 (12.1) 46 (14.3) 124 (10.4) 0.13 
    Weakness     28 (15.4) 46 (14.3) 133 (11.1) 0.11 
    Nausea, vomiting, stomach upset 10 (5.56) 17 (5.3) 53 (4.4) 0.71 
    Constipation 20 (11.0) 37 (11.5) 100 (8.4) 0.15 
    Fatigue 31 (17.0) 62 (19.3) 194 (16.2) 0.42 
    Hives and/or itching 2 (1.1) 19 (5.9) 36 (3.0) 0.08 
    Other 0 3 (0.9) 13 (1.1) 0.04 
If previously taking a statin N=5 N=10 N=34  
    Muscle aches, cramps 1 (20.0) 2 (22.2) 14 (43.8) 0.05 
    Memory loss, forgetfulness, or 
confusion 
0 0 5 (15.6) 0.15 
    Weakness     1 (20.0) 1 (11.1) 6 (18.8) 0.16 
    Nausea, vomiting, stomach upset 0 0 1 (3.1) 0.70 
    Constipation 1 (20.0) 1 (11.1) 2 (6.3) 0.14 
    Fatigue 1 (20.0) 0 7 (21.9) 0.06 
    Hives and/or itching 0 1 (11.1) 0 0.20 
    Other 0 0 2 (6.3) 0. 48 
LDL-C ≥100mg/dL %     
If currently taking a statin N=86 N=137 N=406  
    Muscle aches, cramps 28 (35.4) 47 (35.6) 169 (43.3) 0.18 
    Memory loss, forgetfulness, or 
confusion 
10 (12.8) 21 (15.9) 58 (14.9) 0.83 
    Weakness     13 (16.7) 22 (16.7) 54 (13.9) 0.65 
    Nausea, vomiting, stomach upset 8 (10.3) 5 (3.8) 18 (4.6) 0.09 
    Constipation 8 (10.3) 17 (12.9) 38 (9.7) 0.60 
    Fatigue 15 (19.2) 27 (20.5) 72 (18.5) 0.88 
    Hives and/or itching 2 (2.6) 7 (5.3) 16 (4.1) 0.63 
    Other 0 1 (0.8) 6 (1.5) 0.12 
If previously taking a statin N=20 N=47 N=110  
    Muscle aches, cramps 11 (61.1) 32 (69.6) 65 (63.1) 0.71 
    Memory loss, forgetfulness, or 
confusion 
2 (11.1) 8 (17.4) 7 (6.8) 0.01 
    Weakness     1 (5.6) 14 (30.4) 34 (33.0) 0.06 
    Nausea, vomiting, stomach upset 0 5 (10.9) 6 (5.8) 0.04 
    Constipation 0 5 (10.9) 9 (8.7) 0.04 
    Fatigue 1 (5.6) 15 (32.6) 32 (31.1) 0.07 
    Hives and/or itching 1 (5.6) 5 (10.9) 7 (6.8) 0.06 
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